Article Text

PDF
AB0449 Radiographic change and time-course change in cytokine levels of rheumatoid arthritis patients on etanercept treatment
  1. A. Suda1,
  2. S. Nagaoka1,
  3. H. Furukawa2,
  4. S. Thoma2,
  5. H. Ideguchi3,
  6. S. Ohno3,
  7. Y. Ishigatsubo4
  1. 1Department of Rheumatology, Yokohama Minamikyosai Hospital, Yokohama
  2. 2Department of Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa
  3. 3Center for Rheumatic Diseases, Yokohama City University Medical Center
  4. 4Department of Internal medicine and Immunology, Yokohama city Uniersity, Yokohama, Japan

Abstract

Objectives To study changes in cytokine levels and radiographic findings (mTSS) in rheumatoid arthritis (RA) patients newly treated with etanercept (ETA).

Methods In our 19 pts who started ETA during Nov/2005 - Jan/2007 (2 men; mean age, 62.0 yo; mean disease duration, 8.7 yrs), cytokine (IL-4, IL-6, IL-8, TNFa) levels were determined at baseline, week 4, 24 to assess relationship of RA activity and radiographic findings.

Results Mean DAS28 (ESR) at baseline, & week 4, 24: 6.7, 5.0, 3.8 respectively. Compared to baseline, TNFaat week 24 significantly increased (2.3 vs 96.9). IL-6 significantly decreased (37.4 vs 9.73). Mean mTSS was 92±62 at baseline and 94±64 at week 24; 9 pts achieved radiographic remission (ΔmTSS ≤0.5). Analysis of factors affecting radiographic remission showed no significant variable of patient’s background. Cytokine levels in the remission group appeared to be lower at week 24: IL-4 (91 vs 351), IL-6 (6.8 vs 12.4), IL-8 (5.0 vs 10.8), TNFa (91.0 vs 102.2), but no significant difference.

Conclusions We evaluated the relationship between radiographic remission and cytokine changes in the course of ETA treatment. Although the remission group had a decreasing tendency of IL-4, IL-6, IL-8, TNFaat week 24, no significant difference was seen.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.